Protalix BioTherapeutics, Inc. (PLX) Profit Breakdown
- 2025-12-31: Single Operating -$5.61M.
- 2024-12-31: Single Operating $4.15M.
- 2023-12-31: Single Operating $8.57M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2009-12-31 to 2026-06-30
- Data captured
Profit by product
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest: each year (12 month)
| Fiscal year end | Single Operating |
|---|
| 2025-12-31 | -$5.61M |
|---|
| 2024-12-31 | $4.15M |
|---|
| 2023-12-31 | $8.57M |
|---|
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest: each quarter (3 month)
| Quarter end | Single Operating | Single Reportable |
|---|
| 2026-06-30 | $4.86M | |
|---|
| 2026-03-31 | | $21.14M |
|---|
| 2025-06-30 | $661.00K | |
|---|
| 2025-03-31 | | -$3.73M |
|---|
Net Income (Loss) Attributable to Parent: each year (12 month)
| Fiscal year end | Single Operating |
|---|
| 2025-12-31 | -$6.60M |
|---|
| 2024-12-31 | $2.93M |
|---|
| 2023-12-31 | $8.31M |
|---|
Net Income (Loss) Attributable to Parent: each quarter (3 month)
| Quarter end | Single Operating | Single Reportable |
|---|
| 2026-06-30 | $3.78M | |
|---|
| 2026-03-31 | | $18.32M |
|---|
| 2025-06-30 | $164.00K | |
|---|
| 2025-03-31 | | -$3.62M |
|---|